STAT Examines 7 Questions Surrounding COVID-19 Vaccine Rollout; News Outlets Discuss Vaccine Research, Intellectual Property Issues
STAT: 7 looming questions about the rollout of a Covid-19 vaccine
“…The design, testing, and mass production of multiple vaccines has never been attempted on this type of timeline, making this moment a turning point in the development of vaccines to respond to new disease threats. But the complexity of that work may pale in comparison to what comes next — the rollout of hundreds of millions of doses of never-before-used vaccines across the United States and, eventually, around the world. … Some of the looming problems aren’t foreseeable. But here are some potential hurdles that might complicate this very important effort…” (Branswell/Silverman, 10/9).
Financial Times: AstraZeneca vaccine document shows limit of no-profit pledge (Mancini, 10/7).
The Hill: AstraZeneca’s no-profit pledge for vaccine has expiration date: report (Williams, 10/8).
Nature: What China’s speedy COVID vaccine deployment means for the pandemic (Cyranoski, 10/8).
STAT: Moderna vows not to enforce Covid-19 patents, but advocates say IP should be given to WHO (Silverman, 10/8).